Latest Headlines

Latest Headlines

BrainCells grabs neuropsych therapy in $51M licensing pact

Just six months after gaining control of the mid-stage neuropsychiatric drug sabcomeline through an acquisition of Minster Pharmaceuticals, the UK's Proximagen has inked a deal licensing out its

ALSO NOTED: Acomplia linked to deaths in the U.K.; Does HDL really prevent heart disease?; and much more...

> While the FDA has been slammed by some drugmakers for its too-conservative approach to drug approval, it may have

Stem cell revolutionaries take on big challenges

OncoMed's Michael Clarke, George Q. Daly at the Harvard Stem Cell Institute, Sir Martin Evans from Cardiff University and Rene Hen from BrainCells/Columbia University are among 12 stem cell

BrainCells launches IIa trial after $50M VC round

San Diego-based BrainCells is moving its lead program into a Phase IIa trial after boosting its second venture round with a second tranche. The new money brings its second round to $50 million....